Evercore ISI began coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a note issued to investors on Wednesday, August 16th, MarketBeat.com reports. The brokerage set an “outperform” rating on the stock.
Separately, Zacks Investment Research downgraded shares of Myovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, June 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $18.20.
Myovant Sciences (NASDAQ MYOV) opened at 13.73 on Wednesday. The firm’s 50-day moving average price is $11.25 and its 200-day moving average price is $11.83. The firm’s market cap is $835.39 million. Myovant Sciences has a 12 month low of $9.92 and a 12 month high of $15.50.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP bought a new position in shares of Myovant Sciences during the second quarter worth $648,000. RA Capital Management LLC increased its position in shares of Myovant Sciences by 19.6% in the second quarter. RA Capital Management LLC now owns 2,807,550 shares of the company’s stock worth $32,848,000 after buying an additional 459,128 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Myovant Sciences during the second quarter worth $174,000. Voya Investment Management LLC increased its position in shares of Myovant Sciences by 5.4% in the second quarter. Voya Investment Management LLC now owns 421,397 shares of the company’s stock worth $4,931,000 after buying an additional 21,478 shares during the period. Finally, OxFORD Asset Management LLP increased its position in shares of Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock worth $348,000 after buying an additional 3,971 shares during the period.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
What are top analysts saying about Myovant Sciences Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Myovant Sciences Ltd and related companies.